The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cronos Australia (CAU) has launched its cannabidiol-based sports gel range, FCTR
  • For now, the range includes a warm gel and a cool gel which are designed to help a wide range of athletes with recovery
  • FCTR will initially be sold in Hong Kong and Japan and is not yet available in Australia due to regulatory reasons
  • To speed up distribution, Cronos has signed a sales agency agreement with SS Outdoor
  • On market close for the long weekend, Cronos is up 12.5 per cent and is trading at 13.5 cents per share

Cronos Australia (CAU) has launched its cannabidiol-based sports gel range, FCTR.

FCTR is the company’s second consumer brand, following Bathing Shed, and will initially be sold in Hong Kong and Japan. Due to regulatory reasons, FCTR is not yet available in Australia.

The product is designed to be a recovery for a wide range of athletes. The first two products being launched is a warm gel and cool gel.

FCTR Warm Gel has a warming sensation when applied to the skin and may aid in recovery, whereas FCTR Cool Gel has a cooling sensation when applied to the skin.

Both products are entirely formulated and manufactured in Japan and contain compliant CBD in a rapidly absorbed and residue-free gel.

The products will retail for HKD190 (roughly A$32.40) in Hong Kong and JPY2,273 (roughly A$27.20) in Japan.

To speed up the distribution of FCTR, Cronos has signed a sales agency agreement with SS Outdoor, a Sure Step Asia group company.

Cronos Australia’s Director Nick Mulcahy says elite athletes and their coaching teams have three key concerns about CBD topical products.

“Firstly, they must be pure and compliant with World Anti-Doping Agency guidelines. Secondly, CBD must be made more affordable. Thirdly, athletes want a CBD sports product with the same design, usability and effectiveness standards that they expect from the rest of their gear,” he said.

“With our first two FCTR products, we believe we have successfully addressed each of those concerns,” he added.

On market close for the long weekend, Cronos is up 12.5 per cent and is trading at 13.5 cents per share.

CAU by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…